WallStSmart

Agilent Technologies Inc (A)vsNeoGenomics Inc (NEO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agilent Technologies Inc generates 869% more annual revenue ($7.23B vs $745.97M). A leads profitability with a 19.6% profit margin vs -13.3%. A appears more attractively valued with a PEG of 1.28. A earns a higher WallStSmart Score of 71/100 (B).

A

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 1.99

NEO

Buy

51

out of 100

Grade: C-

Growth: 8.0Profit: 2.0Value: 6.3Quality: 6.5
Piotroski: 3/9Altman Z: 1.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-73.4%)

Margin of Safety

-73.4%

Fair Value

$74.34

Current Price

$135.44

$61.10 premium

UndervaluedFair: $74.34Overvalued
NEOUndervalued (+77.8%)

Margin of Safety

+77.8%

Fair Value

$51.46

Current Price

$10.90

$40.56 discount

UndervaluedFair: $51.46Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 9.0/10
EPS GrowthGrowth
60.0%10/10

Earnings expanding 60.0% YoY

Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

NEO2 strengths · Avg: 9.0/10
EPS GrowthGrowth
130.6%10/10

Earnings expanding 130.6% YoY

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Areas to Watch

A3 concerns · Avg: 3.7/10
P/E RatioValuation
26.0x4/10

Moderate valuation

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NEO4 concerns · Avg: 3.0/10
PEG RatioValuation
2.094/10

Expensive relative to growth rate

Market CapQuality
$1.37B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-12.0%2/10

ROE of -12.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on EPS Growth, Operating Margin. Profitability is solid with margins at 19.6% and operating margin at 23.7%. PEG of 1.28 suggests the stock is reasonably priced for its growth.

Bull Case : NEO

The strongest argument for NEO centers on EPS Growth, Price/Book. Revenue growth of 11.1% demonstrates continued momentum.

Bear Case : A

The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.

Bear Case : NEO

The primary concerns for NEO are PEG Ratio, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

A profiles as a mature stock while NEO is a turnaround play — different risk/reward profiles.

NEO carries more volatility with a beta of 1.80 — expect wider price swings.

NEO is growing revenue faster at 11.1% — sustainability is the question.

A generates stronger free cash flow (184M), providing more financial flexibility.

Bottom Line

A scores higher overall (71/100 vs 51/100), backed by strong 19.6% margins. NEO offers better value entry with a 77.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

NeoGenomics Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.

Want to dig deeper into these stocks?